Sun, Jan 25, 2015, 11:37 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Arrayit Corporation Message Board

opusmagnum77 6 posts  |  Last Activity: Dec 31, 2014 4:37 PM Member since: Nov 26, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Arrayit put out its own PR today about the deal

    by biotechinvstr Dec 31, 2014 11:00 AM
    opusmagnum77 opusmagnum77 Dec 31, 2014 4:37 PM Flag

    I think what you saw the last few days, and at at the end of the trading session today, was "tax loss selling" to minimize capital gains from other sources.

    Up to around 11 am ARYC was up 30% to 40% trading in the 0.13 - 0.14 range and volume of 180,000. After that the sellers started playing games to get the stock down...starting with a 100 sell order at 0.054 ...really...although the highest bid on level 2 was 0.105 at that time.

    Now that he window for tax loss selling is closed, Friday will tell.

    Happy New Year!

  • Reply to

    USDA news

    by dr.teerex Dec 10, 2014 10:24 AM
    opusmagnum77 opusmagnum77 Dec 11, 2014 10:47 AM Flag

    Now that the market has had time to digest yesterday's news the pps is responding UP.

  • Reply to

    USDA news

    by dr.teerex Dec 10, 2014 10:24 AM
    opusmagnum77 opusmagnum77 Dec 10, 2014 12:06 PM Flag

    and your personal opinion is worth even less bto

  • Reply to

    USDA news

    by dr.teerex Dec 10, 2014 10:24 AM
    opusmagnum77 opusmagnum77 Dec 10, 2014 11:00 AM Flag

    I think it's meaningful if they can actually commercialize the test. The market is skeptical because of so many promising things that they have announced over the years that have gone nowhere.
    Izzy and his associates are behind the Array Molecular company that was created to commercialize this test. So maybe this test will actually get off the ground.

    SUNNYVALE, California โ€“ September 15, 2014โ€“ Arrayit Corporation (OTCBB: ARYC) announces that on August 19, 2014, Arrayit Corporation entered into an agreement with Array Molecular Corp., a corporation owned by certain individual investors of Arrayit, including Irwin Zalcberg and Reuben Taub, to commercialize a DNA microarray platform for detecting pathogens in food. Under the terms of the agreement, Arrayit Corporation will contribute a license to its patents and all intellectual property associated with this test in exchange for 24% of the outstanding shares of Array Molecular. Array Molecular will provide at least $2 million toward the commercialization effort.

  • Reply to

    Interesting article describing Avant plans

    by opusmagnum77 Nov 23, 2014 10:56 AM
    opusmagnum77 opusmagnum77 Nov 23, 2014 11:07 AM Flag

    yahoo would not let me post the rest of the article.
    if you want you can read it on ihub POST # 4885

  • Avant Going Public via American Liberty Petroleum Reverse Merger; Planning FDA Submission for OvaDx

    Posted on ihub...
    Sep 26, 2014 | Adam Bonislawski

    NEW YORK (GenomeWeb) โ€“ Avant Diagnostics plans to go public through a reverse merger effective Oct. 1, after which it will begin preparing a US Food and Drug Administration 510(k) submission for its proteomic ovarian cancer test OvaDx, Greg Linn, the company's CFO and COO told ProteoMonitor this week.

    Under the plan, Avant will merge with Houston-based oil company American Liberty Petroleum, which announced its acquisition of Avant last week in an 8-K filing with the US Securities and Exchange Commission. The new entity will then change its name to Avant and list on the Over-The-Counter Bulletin Board.

    The move satisfies requirements of the settlement of a lawsuit filed March 31 by Avant against its former parent company Arrayit, in which Avant accused Arrayit of breach of contract, fraud, negligent misrepresentation, and other cases of action.

    Under the settlement, which the parties reached Aug. 6, Arrayit retained the right to manufacture the OvaDx test, and Avant retained its right to sell and market OvaDx upon US Food and Drug Administration clearance. However, Avant was required to become a publicly traded company within one year of the agreement or else commercialization rights for the test would revert back to Arrayit, which still holds a minority stake in Avant.

    "Our business plan called for us to go public upon FDA approval for monitoring of OvaDX," Linn said. "Arrayit wanted us to go public about a year sooner, and so as [part of the] settlement we agreed [to go public earlier]."

    ALP CEO Robert Rhodes is a past investor in Avant and Linn has previously done business with him and ALP CFO Steven Plumb, which factored in the decision to use the company as a vehicle for the reverse merger, Linn said.

    continued on next post.....

0.095+0.025(+35.91%)Jan 23 2:42 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.